Long acting injectable antipsychotics: Uninterrupted use during the COVID‐19 pandemic

Nystazaki, Maria; Karanikola, Maria

doi:10.1111/jpm.12750

Cited by 6 publications

(6 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Switching from LAI therapy to reduce potential in-office exposure during the pandemic should be viewed as a choice of last resort. To ensure continuity of care while prioritizing patient and staff safety during the pandemic, recommendations include the development of new protocols which include guidance for patients on safely approaching LAI clinics and screening for COVID-19 symptoms by phone prior to arrival and guidance for patients and staff on use of proper personal protective equipment against COVID-19 [44].…”

Section: Discussionmentioning

confidence: 99%

The post COVID-19 healthcare landscape and the use of long-acting injectable antipsychotics for individuals with schizophrenia and bipolar I disorder: the importance of an integrated collaborative-care approach

Correll

Chepke²,

Gionfriddo

et al. 2022

BMC Psychiatry

View full text Add to dashboard Cite

Background Long-acting injectable antipsychotics (LAIs) are an essential maintenance treatment option for individuals with schizophrenia or bipolar I disorder (BP-I). This report summarizes a roundtable discussion on the impact of COVID-19 on the mental healthcare landscape and use of LAIs for individuals with schizophrenia or BP-I. Methods Ten experts and stakeholders from diverse fields of healthcare participated in a roundtable discussion on the impact of the COVID-19 pandemic, treatment challenges, and gaps in healthcare for individuals with schizophrenia or BP-I, informed by a literature search. Results Individuals with schizophrenia or BP-I are at increased risk of COVID-19 infection and increased risk of mortality after COVID-19 diagnosis. LAI prescriptions decreased early on in the pandemic, driven by a decrease in face-to-face consultations. Mental healthcare services are adapting with increased use of telehealth and home-based treatment. Clinical workflows to provide consistent, in-person LAI services include screening for COVID-19 exposure and infection, minimizing contact, and ensuring mask-wearing by individuals and staff. The importance of continued in-person visits for LAIs needs to be discussed so that staff can share that information with patients, their caregivers, and families. A fully integrated, collaborative-care model is the most important aspect of care for individuals with schizophrenia or BP-I during and after the COVID-19 pandemic. Conclusions The COVID-19 pandemic has highlighted the importance of a fully integrated collaborative-care model to ensure regular, routine healthcare contact and access to prescribed treatments and services for individuals with schizophrenia and BP-I.

show abstract

Section: Discussionmentioning

confidence: 99%

The post COVID-19 healthcare landscape and the use of long-acting injectable antipsychotics for individuals with schizophrenia and bipolar I disorder: the importance of an integrated collaborative-care approach

Correll

Chepke²,

Gionfriddo

et al. 2022

BMC Psychiatry

View full text Add to dashboard Cite

show abstract

“…cited the availability of community resources to support ongoing treatment as a critical factor in switching to LAIs during the COVID‐19 pandemic. Notably, users of community services and their families who maintained optimal therapeutic relationships with experienced nursing teams received person‐centered, ongoing care even during the COVID‐19 pandemic 23 …”

Section: Maintenance Therapy For Schizophrenia Using Lais During the ...mentioning

confidence: 99%

Long‐acting injectable antipsychotics as maintenance therapy for schizophrenia during the COVID‐19 pandemic: A micro‐narrative review

Oguchi,

Miyake,

Ando

2024

Neuropsychopharm Rep

View full text Add to dashboard Cite

The coronavirus disease pandemic has presented healthcare systems with unprecedented challenges globally and substantially impacted the management of chronic diseases such as schizophrenia. This narrative review highlights the usefulness of long‐acting injectable antipsychotics (LAIs) as maintenance therapy for patients with schizophrenia during the pandemic. The analysis of relevant literature and psychiatric survey data revealed diverse trends in LAIs prescription and patient adherence with oral antipsychotics. Although some studies have reported a decrease in LAIs prescriptions owing to pandemic‐related disruptions, others have suggested stable patient adherence with oral antipsychotics. Approximately 70% of Japanese psychiatrists reported an increase in schizophrenia relapse rates in a survey, underscoring the critical role of LAIs in maintaining therapeutic stability. The potential benefits of LAIs with extended dosing intervals have been highlighted, including improving oral medication adherence and reducing the frequency of hospital visits. In conclusion, this review emphasizes the continued need for uninterrupted LAIs therapy in conjunction with community and home‐based care despite the disruptions caused by the coronavirus disease pandemic. Further development of LAIs maintenance therapy strategies considering the ongoing pandemic and potential future public health emergencies are required.

show abstract

“…The prescription of long-acting injectable antipsychotics (LAI) has been a challenge in many countries with various results [44][45][46][47][48][49][50][51][52][53][54][55]. In the United States, Canada, Italy, and Greece, no significant increase of LAI disruption has been identified in electronic records [25,44,45,53]. In Romania, a decrease of 48% of LAI initiation was identified in the 12 months following the COVID-19 onset compared with the 12 months before in a mirror study [46].…”

Section: Key Pointsmentioning

confidence: 99%

Section: Key Pointsmentioning

confidence: 99%

Lessons from the coronavirus disease 2019 pandemic in schizophrenia: a review

Fond

Boyer

2023

Current Opinion in Psychiatry

View full text Add to dashboard Cite

Purpose of reviewMultiple countries have reported increased COVID-19 mortality in patients with schizophrenia. The purpose of this review was to synthetize the consequences of the pandemic on patients with schizophrenia including vaccination data.Recent findingsWe have synthetized data on the increased risk of infection and increased mortality, the impact of the pandemic and lockdowns on psychiatric care, vaccination policies, unwillingness to vaccine in patients and the rates of vaccination.SummarySchizophrenia has been confirmed at increased risk of both COVID-19 infection and developing a severe/lethal form of the infection. Patients with schizophrenia should, therefore, be prioritized for vaccination whenever possible and should be prioritized for psychiatric and somatic care access. Psychotic symptomatology may be a barrier to vaccination in some patients, and heterogenous vaccination rates were identified in national databases. The COVID-19 pandemic has been also a unique opportunity to develop telehealth. A mixed face-to-face and distance model should be encouraged, whenever possible, to improve the experience of patients, relatives and healthcare professionals. No major change of long-acting antipsychotics has been reported in most countries, and there was no consistent evidence for clozapine prescription to increase the risk of COVID-19 infection or severe outcomes.

show abstract

Long acting injectable antipsychotics: Uninterrupted use during the COVID‐19 pandemic

Cited by 6 publications

References 6 publications

The post COVID-19 healthcare landscape and the use of long-acting injectable antipsychotics for individuals with schizophrenia and bipolar I disorder: the importance of an integrated collaborative-care approach

The post COVID-19 healthcare landscape and the use of long-acting injectable antipsychotics for individuals with schizophrenia and bipolar I disorder: the importance of an integrated collaborative-care approach

Long‐acting injectable antipsychotics as maintenance therapy for schizophrenia during the COVID‐19 pandemic: A micro‐narrative review

Lessons from the coronavirus disease 2019 pandemic in schizophrenia: a review

Contact Info

Product

Resources

About